Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design

Comorbidities may differently affect treatment response and cause-specific outcomes in heart failure (HF) with preserved (HFpEF) vs. mid-range/mildly-reduced (HFmrEF) vs. reduced (HFrEF) ejection fraction (EF), complicating trial design. In patients with HF, we performed a comprehensive analysis of type 2 diabetes (T2DM), atrial fibrillation (AF) chronic kidney disease (CKD), and cause-specific outcomes.

Source: International Journal of Cardiology - April 29, 2020 Category: Cardiology Authors: Gianluigi Savarese, Camilla Settergren, Benedikt Schrage, Tonje Thorvaldsen, Ida L öfman, Ulrik Sartipy, Linda Mellbin, Andrea Meyers, Soulmaz Fazeli Farsani, Martina Brueckmann, Kimberly G. Brodovicz, Ola Vedin, Folkert W. Asselbergs, Ulf Dahlström, Fr Source Type: research